Diabetics who use rosiglitazone have an increased incidence of bladder cancer, Korean researchers reported in Medicine (2016;95:e2786).

In a nested case-control study that included 47,738 patients with diabetes, investigators found that exclusive rosiglitazone use was associated with 3-fold increased odds of bladder cancer compared with non-use. The risk of bladder cancer started to rise after less than 3 months of use and peaked at 3–12 months of use (4.5-fold increased odds).

Continue Reading